BNP Paribas Financial Markets
SPRY icon

BNP Paribas Financial Markets’s ARS Pharmaceuticals SPRY Stock Holding History

BNP Paribas Financial Markets’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.7K Sell
12,317
-7,824
-39% -$67.3K ﹤0.01% 4558
2026
Q1 		$162K Buy
20,141
+13,734
+214% +$132K ﹤0.01% 4140
2025
Q4 		$74.6K Sell
6,407
-6,124
-49% -$59.6K ﹤0.01% 4501
2025
Q3 		$126K Buy
12,531
+6,434
+106% +$92.3K ﹤0.01% 4203
2025
Q2 		$106K Buy
6,097
+2,245
+58% +$32.4K ﹤0.01% 3994
2025
Q1 		$48.5K Sell
3,852
-3,278
-46% -$39.4K ﹤0.01% 4301
2024
Q4 		$75.2K Buy
+7,130
New +$99.9K ﹤0.01% 4274
2022
Q4 		– Sell
-456
Closed -$2.41K – 4564
2022
Q3 		$2.41K Buy
+456
New +$2.25K ﹤0.01% 4327

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets's SPRY Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its ARS Pharmaceuticals (SPRY) stake by 39% in Q2 2026, selling an estimated $67.3K and leaving 12,317 shares worth $98.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4558.

BNP Paribas Financial Markets first reported a position in SPRY in Q3 2022 and has held it in 8 quarters since. The position peaked at $162K in Q1 2026. 192 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • BNP Paribas Financial Markets held 12,317 shares of ARS Pharmaceuticals worth $98.7K as of Q2 2026.
  • BNP Paribas Financial Markets sold 7,824 ARS Pharmaceuticals shares in Q2 2026, an estimated $67.3K.
  • ARS Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4558 holding.
  • BNP Paribas Financial Markets first reported a position in ARS Pharmaceuticals in Q3 2022 and has held it in 8 quarters since.
  • BNP Paribas Financial Markets's ARS Pharmaceuticals position peaked at $162K in Q1 2026.
  • 192 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.